Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 5/2004

Open Access 01-10-2004 | Research article

Activated leukocyte cell adhesion molecule in breast cancer: prognostic indicator

Authors: Judy A King, Solomon F Ofori-Acquah, Troy Stevens, Abu-Bakr Al-Mehdi, Oystein Fodstad, Wen G Jiang

Published in: Breast Cancer Research | Issue 5/2004

Login to get access

Abstract

Introduction

Activated leukocyte cell adhesion molecule (ALCAM) (CD166) is an immunoglobulin molecule that has been implicated in cell migration. The present study examined the expression of ALCAM in human breast cancer and assessed its prognostic value.

Methods

The immunohistochemical distribution and location of ALCAM was assessed in normal breast tissue and carcinoma. The levels of ALCAM transcripts in frozen tissue (normal breast, n = 32; breast cancer, n = 120) were determined using real-time quantitative PCR. The results were then analyzed in relation to clinical data including the tumor type, the grade, the nodal involvement, distant metastases, the tumor, node, metastasis (TNM) stage, the Nottingham Prognostic Index (NPI), and survival over a 6-year follow-up period.

Results

Immunohistochemical staining on tissue sections in ducts/acini in normal breast and in breast carcinoma was ALCAM-positive. Differences in the number of ALCAM transcripts were found in different types of breast cancer. The level of ALCAM transcripts was lower (P = 0.05) in tumors from patients who had metastases to regional lymph nodes compared with those patients without, in higher grade tumors compared with Grade 1 tumors (P < 0.01), and in TNM Stage 3 tumors compared with TNM Stage 1 tumors (P < 0.01). Tumors from patients with poor prognosis (with NPI > 5.4) had significantly lower levels (P = 0.014) of ALCAM transcripts compared with patients with good prognosis (with NPI < 3.4), and tumors from patients with local recurrence had significantly lower levels than those patients without local recurrence or metastases (P = 0.04). Notably, tumors from patients who died of breast cancer had significantly lower levels of ALCAM transcripts (P = 0.0041) than those with primary tumors but no metastatic disease or local recurrence. Patients with low levels of ALCAM transcripts had significantly (P = 0.009) more incidents (metastasis, recurrence, death) compared with patients with primary breast tumors with high levels of ALCAM transcripts.

Conclusions

In the present panel of breast cancer specimens, decreased levels of ALCAM correlated with the nodal involvement, the grade, the TNM stage, the NPI, and the clinical outcome (local recurrence and death). The data suggest that decreased ALCAM expression is of clinical significance in breast cancer, and that reduced expression indicates a more aggressive phenotype and poor prognosis.
Appendix
Available only for authorised users
Literature
1.
American Cancer Society: Cancer Facts & Figures 2004. Atlanta, GA. 2004
2.
Breast. In AJCC Cancer Staging Manual. Edited by: Fleming I, Cooper J, Henson D, Hutter R, Kennedy B, Murphy G, O'Sullivan B, Sobin L, Yarbro J. 1997, Philadelphia: Lippincott-Raven, 171-178. fifth
3.
Pourquie O, Corbel C, Le Caer J-P, Rossier J, Le Douarin N: BEN, a surface glycoprotein of the immunoglobulin superfamily, is expressed in a variety of developing systems. Proc Natl Acad Sci USA. 1992, 89: 5261-5265.CrossRefPubMedPubMedCentral
4.
Tanaka H, Matsui T, Agata A, Tomura M, Kubota I, McFarland KC, Kohr B, Lee A, Phillips HS, Shelton DL: Molecular cloning and expression of a novel adhesion molecule, SC1. Neuron. 1991, 7: 535-545. 10.1016/0896-6273(91)90366-8.CrossRefPubMed
5.
Burns F, von Kannen S, Guy L, Raper J, Kamholz J, Chang S: DM-GRASP, a novel immunoglobulin superfamily axonal surface protein that supports neurite extension. Neuron. 1991, 7: 209-220. 10.1016/0896-6273(91)90259-3.CrossRefPubMed
6.
Peduzzi J, Irwin M, Geisert E: Distribution and characteristics of a 90 kDa protein, KG-CAM in the rat CNS. Brain Res. 1994, 640: 296-307. 10.1016/0006-8993(94)91885-6.CrossRefPubMed
7.
Paschke K, Lottspeich F, Stuermer C: Neurolin, a cell surface glycoprotein on growing retinal axons in the goldfish visual systems, is reexpressed during retinal axonal regeneration. J Cell Biol. 1992, 117: 863-875. 10.1083/jcb.117.4.863.CrossRefPubMed
8.
Degen W, van Kempen L, Gijzen E, van Groningen J, van Kooyk Y, Bloemers H, Swart G: MEMD, a new cell adhesion molecule in metastasizing human melanoma cell lines, is identical to ALCAM (activated leukocyte cell adhesion molecule). Am J Pathol. 1998, 152: 805-813.PubMedPubMedCentral
9.
Bowen MA, DD Patel, Li X, Modrell B, Malacko AR, Wang W-C, Marquardt H, Neubauer M, Pesando JM, Francke U, Haynes BF, Aruffo A: Cloning, mapping, and characterization of activated leukocyte-cell adhesion molecule (ALCAM), a CD6 ligand. J Exp Med. 1995, 181: 2213-2220. 10.1084/jem.181.6.2213.CrossRefPubMed
10.
Bowen MA, Bajorath J, D'Egidio M, Whitney GS, Palmer D, Kobarg J, Starling GC, Siadak AW, Aruffo A: Characterization of mouse ALCAM (CD166): the CD6-binding domain is conserved in different homologs and mediates cross-species binding. Eur J Immunol. 1997, 27: 1469-1478.CrossRefPubMed
11.
Kurata H, Matsumoto A, Fujiwara Y, Kondo K, Itakura H, Mitchell A, Fidge N: A candidate high density lipoprotein (HDL) receptor, HB2, with possible multiple functions shows sequence homology with adhesion molecules. J Atheroscler Thromb. 1998, 4: 112-117.CrossRefPubMed
12.
Matsumoto A, Mitchell A, Kurata H, Pyle L, Kondo K, Itakura H, Fidge N: Cloning and characterization of HB2, a candidate high density lipoprotein receptor. Sequence homology with members of the immunoglobulin superfamily of membrane proteins. J Biol Chem. 1997, 272: 16778-16782. 10.1074/jbc.272.27.16778.CrossRefPubMed
13.
Swart GWM: Activated leukocyte cell adhesion molecule (CD 166/ALCAM): developmental and mechanistic aspects of cell clustering and cell migration. Eur J Cell Biol. 2002, 81: 313-321.CrossRefPubMed
14.
van Kempen LCLT, Nelissen JMDT, Degen WGJ, Torensma R, Weidle UH, Bloemers HPJ, Figdor CF, Swart GWM: Molecular basis for the homophilic activated leukocyte cell adhesion molecule (ALCAM)–ALCAM interaction. J Biol Chem. 2001, 276: 25783-25790. 10.1074/jbc.M011272200.CrossRefPubMed
15.
Ohneda O, Ohneda K, Arai F, Lee J, Miyamoto T, Fukushima Y, Dowbenko D, Lasky LA, Suda T: ALCAM (CD166): its role in hematopoietic and endothelial development. Blood. 2001, 98: 2134-2142. 10.1182/blood.V98.7.2134.CrossRefPubMed
16.
Arai F, Ohneda O, Miyamoto T, Zhang X, Suda T: Mesenchymal stem cells in perichondrium express activated leukocyte cell adhesion molecule and participate in bone marrow formation. J Exp Med. 2002, 195: 1549-1563. 10.1084/jem.20011700.CrossRefPubMedPubMedCentral
17.
van Kempen LCLT, van den Oord JJ, van Muijen GNP, Weidle UH, Bloemers HPJ, Swart GWM: Activated leukocyte cell adhesion molecule/CD166, a marker of tumor progression in primary malignant melanoma of the skin. Am J Pathol. 2000, 156: 769-774.CrossRefPubMedPubMedCentral
18.
Kristiansen G, Pilarsky C, Wissmann C, Stephan C, Weissbach L, Loy V, Loening S, Dietel M, Rosenthal A: ALCAM/CD166 is up-regulated in low-grade prostate cancer and progressively lost in high-grade lesions. The Prostate. 2003, 54: 34-43. 10.1002/pros.10161.CrossRefPubMed
19.
King JA, Al-Mehdi A-B, Ofori-Acquah SF, Stevens T: Role of ALCAM in interaction of breast cancer metastases and the endothelium of the lung [abstract]. FASEB J. 2004, 18: A330-
20.
Jiang WG, Douglas-Jones A, Mansel RE: Level of expression of lipoxygenases and cyclooxygenase-2 in human breast cancer. Prostaglandins Leukot Essent Fatty Acids. 2003, 69: 275-281. 10.1016/S0952-3278(03)00110-8.CrossRefPubMed
21.
Jiang WG, Douglas-Jones A, Mansel RE: Expression of peroxisome-proliferator activated receptor-gamma (PPARγ) and the PPARgamma co-activator, PGC-1 in human breast cancer correlates with clinical outcomes. Int J Cancer. 2003, 106: 752-757. 10.1002/ijc.11302.CrossRefPubMed
22.
Jiang WG, Watkins G, Lane J, Cunnick GH, Douglas-Jones A, Mokbel K, Mansel RE: Prognostic value of Rho GTPases and Rho guanine nucleotide dissociation inhibitors in human breast cancers. Clin Cancer Res. 2003, 9: 6432-6440.PubMed
23.
Parr C, Watkins G, Mansel RE, Jiang WG: The hepatocyte growth factor regulatory factors in human breast cancer. Clin Cancer Res. 2004, 10: 202-211.CrossRefPubMed
24.
Al-Rawi MA, Rmali K, Watkins G, Mansel RE, Jiang WG: Aberrant expression of interleukin-7 (IL-7) and its signaling complex in human breast cancer. Eur J Cancer. 2004, 40: 494-502. 10.1016/j.ejca.2003.10.016.CrossRefPubMed
25.
Davies G, Cunnick GH, Mansel RE, Mason MD, Jiang WG: Levels of expression of endothelial markers specific to tumour-associated endothelial cells and their correlation with prognosis in patients with breast cancer. Clin Exp Metastasis. 2004, 21: 31-37. 10.1023/B:CLIN.0000017168.83616.d0.CrossRefPubMed
26.
Nazarenko IA, Bhatnagar SK, Hohman RJ: A closed tube format for amplification and detection of DNA based on energy transfer. Nucleic Acids Res. 1997, 25: 2516-2521. 10.1093/nar/25.12.2516.CrossRefPubMedPubMedCentral
27.
Somlyo AV, Bradshaw D, Ramos S, Murphy C, Myers CE, Somlyo AP: Rho-kinase inhibitor retards migration and in vivo dissemination of human prostate cancer cells. Biochem Biophy Res Commun. 2000, 269: 652-659. 10.1006/bbrc.2000.2343.CrossRef
28.
Cunnick GH, Jiang WG, Gomez KF, Mansel RE: Lymphangiogenesis quantification using quantitative PCR and breast cancer as a model. Biochem Biophys Res Commun. 2001, 288: 1043-1046. 10.1006/bbrc.2001.5869.CrossRefPubMed
29.
Davies G, Jiang WG, Mason MD: Cell–cell adhesion molecules and signaling intermediates and their role in the invasive potential of prostate cancer cells. J Urol. 2000, 163: 985-992. 10.1097/00005392-200003000-00084.CrossRefPubMed
30.
Kuniyasu H, Ellis LM, Evans DB, Abbruzzese JL, Fenoglio CJ, Bucana CD, Cleary KR, Tahara E, Fidler IJ: Relative expression of E-cadherin and type IV collagenase genes predicts disease outcome in patients with resectable pancreatic carcinoma. Clin Cancer Res. 1999, 5: 25-33.PubMed
31.
Uchida N, Yang Z, Combs J, Pourquie O, Nguyen M, Ramanathan R, Fu J, Welply A, Chen S, Weddell G, Sharma AK, Leiby KR, Karagogeos D, Hill B, Humeau L, Stallcup WB, Hoffman R, Tsukamoto AS, Gearing DP, Peault B: The characterization, molecular cloning, and expression of a novel hematopoietic cell antigen from CD34+ human bone marrow cells. Blood. 1997, 89: 2706-2716.PubMed
32.
Stephan J-P, Bald L, Roberts PE, Lee J, Gu Q, Mather JP: Distribution and function of the adhesion molecule BEN during rat development. Dev Biol. 1999, 212: 264-277. 10.1006/dbio.1999.9348.CrossRefPubMed
33.
Corbel C, Bluestein HG, Pourquie O, Vaigot P, Le Douarin NM: An antigen expressed by avian neuronal cells is also expressed by activated T lymphocytes. Cell Immunol. 1992, 141: 99-110.CrossRefPubMed
34.
Corbel C, Pourquie O, Cormier F, Vaigot P, Le Douarin NM: BEN/SC1/DM-GRASP, a homophilic adhesion molecule, is required for in vitro myeloid colony formation by avian hemopoietic progenitors. Proc Natl Acad Sci USA. 1996, 93: 2844-2849. 10.1073/pnas.93.7.2844.CrossRefPubMedPubMedCentral
35.
Moll R, Mitze M, Frixen UH, Birchmeier W: Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas. Am J Pathol. 1993, 143: 1731-1742.PubMedPubMedCentral
36.
Goldstein NS, Bassi D, Watts JC, Layfield LJ, Yaziji H, Gown AM: E-cadherin reactivity of 95 noninvasive ductal and lobular lesions of the breast. Implications for the interpretation of problematic lesions. Am J Clin Pathol. 2001, 115: 534-542. 10.1309/B0DD-4M7H-GJG1-7KCW.CrossRefPubMed
37.
Acs G, Lawton TJ, Rebbeck TR, LiVolsi VA, Zhang PJ: Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications. Am J Clin Pathol. 2001, 115: 85-98. 10.1309/FDHX-L92R-BATQ-2GE0.CrossRefPubMed
38.
Jiang WG: E-cadherin and its associated protein catenins, cancer invasion and metastasis. Br J Surg. 1996, 83: 437-446.CrossRefPubMed
39.
Ellis I, Pinder S, Lee A, Elston C: Tumors of the breast. In Diagnostic Histopathology of Tumors. Edited by: Fletcher C. 2000, New York: Churchill Livingstone, 865-930. second
40.
Galea MH, Blamey RW, Elston CE, Ellis IO: The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat. 1992, 22: 207-219.CrossRefPubMed
41.
Miller W, Ellis I, Sainsbury J, Dixon J: ABC of breast diseases. Prognostic factors. Br J Med. 1994, 309: 1573-1576.CrossRef
42.
Tomita K, van Bokhoven A, Jansen CFJ, Bussemakers MJG, Schalken JA: Coordinate recruitment of E-cadherin and ALCAM to cell-cell contacts by a-catenin. Biochem Biophy Res Commun. 2000, 267: 870-874. 10.1006/bbrc.1999.2040.CrossRef
Metadata
Title
Activated leukocyte cell adhesion molecule in breast cancer: prognostic indicator
Authors
Judy A King
Solomon F Ofori-Acquah
Troy Stevens
Abu-Bakr Al-Mehdi
Oystein Fodstad
Wen G Jiang
Publication date
01-10-2004
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 5/2004
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr815

Other articles of this Issue 5/2004

Breast Cancer Research 5/2004 Go to the issue

Commentary

A multigene RT-PCR assay used to predict recurrence in early breast cancer: two presentations with contradictory results

Review

New targets for therapy in breast cancer: Mammalian target of rapamycin (mTOR) antagonists

Research article

Reduced expression of p27 is a novel mechanism of docetaxel resistance in breast cancer cells

Research article

UDP-glucuronosyltransferase and sulfotransferase polymorphisms, sex hormone concentrations, and tumor receptor status in breast cancer patients

Commentary

Low-molecular-weight cyclin E: the missing link between biology and clinical outcome

Research article

Chromosomal instability and lack of cyclin E regulation in hCdc4 mutant human breast cancer cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits